首页> 外文期刊>Clinical oncology >Primary radiotherapy for carcinoma of the retromolar trigone: a useful alternative to surgery.
【24h】

Primary radiotherapy for carcinoma of the retromolar trigone: a useful alternative to surgery.

机译:磨牙后三角骨癌的原发放疗:一种有效的手术替代方法。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: Squamous cell carcinoma of the retromolar trigone is uncommon. The standard initial treatment is primary surgery, which usually involves microvascular reconstruction with a composite flap. Some patients are considered unsuitable for this procedure. This retrospective study examined the outcome and toxicity for patients with squamous cell carcinoma of the retromolar trigone treated with definitive radiotherapy in a single centre. MATERIALS AND METHODS: Between 1991 and 2000, 43 patients were treated with definitive radiotherapy with a median dose of 50Gy in 16 fractions over 21 days. Hospital case notes and radiotherapy records were analysed. RESULTS: The median age was 66 years (range 39-84 years). Nodal disease was evident in 13 (30.2%) patients. Twenty-one patients (51.2%) had stage I/II disease and 20 patients (48.8%) had stage III/IV disease. After a median follow-up of 59 months, 13 (30.2%) patients were alive and well, nine (20.9%) patients had died of an intercurrent illness and 21 (48.8%) had died of their disease. Five-year locoregional control was 46.5% (95% confidence interval 29.7-61.7), cause-specific survival was 45.7% (95% confidence interval 29.1-60.8) and overall survival was 30.9% (95% confidence interval 17.5-46.3). Osteoradionecrosis was documented in two patients. DISCUSSION: This hypofractionated regimen is convenient for this patient population and produced comparable outcomes to longer fractionation schedules without an increase in late toxicity.
机译:目的:磨牙后三角骨的鳞状细胞癌并不常见。标准的初始治疗是初级手术,通常涉及使用复合皮瓣进行微血管重建。一些患者被认为不适合该手术。这项回顾性研究在单个中心检查了接受明确放疗的后磨牙三角骨鳞状细胞癌患者的结局和毒性。材料与方法:1991年至2000年间,有43例患者接受了确定性放疗,中位剂量为50Gy,分21天内进行16天治疗。分析了住院病例记录和放疗记录。结果:中位年龄为66岁(39-84岁)。 13例(30.2%)的患者明显出现淋巴结病。 21例(51.2%)患有I / II期疾病,20例(48.8%)患有III / IV期疾病。在中位随访59个月后,有13例(30.2%)病人还活着并且状况良好,其中9例(20.9%)死于并发疾病,21例(48.8%)死于疾病。五年局部区域控制率为46.5%(95%置信区间29.7-61.7),特定原因生存率为45.7%(95%置信区间29.1-60.8),总生存率为30.9%(95%置信区间17.5-46.3)。两名患者记录了骨放射性坏死。讨论:这种低分割方案对于该患者人群是方便的,并且产生了与更长的分割方案相当的结果,而没有增加后期毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号